A rapid increase in the number of hospital-acquired cases of Clostridium difficile in Austria has been reported. The causative agent of pseudomembranous colitis is increasing in the United States, Canada, Asia and Europe. In Austria, C. difficile type 027 is increasing. The incidence of C. difficile-associated disease (CDAD) due to type 027 is increasing in the United States, Canada, Asia and Europe. In Austria, C. difficile type 027 has so far only been discovered once, in a British tourist with pseudomembranous colitis in 2006. In April 2008, C. difficile PCR ribotype 027 was found in two cases of C. difficile-associated disease affecting Austrian citizens treated in hospitals in Vienna and Graz, Austria.

Case reports

In Austria, Clostridium difficile is the leading cause of community-acquired bacterial diarrheal illness and the most frequently identified cause of hospital-acquired diarrhea. C. difficile-associated disease is associated with a higher case-fatality-ratio than other types. This increased virulence is associated with two deletions in a toxin regulator gene resulting in hyperproduction of toxins A and B. The incidence of C. difficile-associated disease (CDAD) due to type 027 is increasing in the United States, Canada, Asia and Europe. In Austria, C. difficile type 027 has so far only been discovered once, in a British tourist with pseudomembranous colitis in 2006. In April 2008, C. difficile PCR ribotype 027 was found in two cases of C. difficile-associated disease affecting Austrian citizens treated in hospitals in Vienna and Graz, Austria.

Laboratory characterisation

Stool specimens of both patients were positive for C. difficile. The isolates were further characterised by the Austrian Agency for Health and Food Safety (AGES) in April 2008 as C. difficile PCR ribotype 027 by PCR ribotyping. Both isolates contained the genes for toxin A, toxin B, and the binary toxin. In addition, an 18 base pair deletion in tcdC was present. The two isolates differed from each other by 18 repeats at locus A, by 9 repeats at locus B, by 4 repeats at locus C, and by 2 repeats at locus E; no data are available for locus G. The differences indicate that the two isolates must not be considered as clonal. Susceptibility testing by E-tests revealed patterns of clindamycin-susceptible and fluoroquinolone-susceptible type 027; moxifloxacin

EUROSURVEILLANCE Vol. 13 · Issues 4-6 · Apr-Jun 2008 · www.eurosurveillance.org
resistance was determined using a breakpoint of < 2 μg/ml for susceptible. Disc diffusion tests revealed erythromycin resistance for both isolates. This pattern is different from that of the major European 027 strains [9,10].

Conclusion

Although we hypothesize that both Austrian patients had community-acquired infections of C. difficile PCR ribotype 027 and suffered severe illness, important questions remain unanswered for both cases. We cannot exclude that the female hospital employee had a healthcare-acquired infection with community onset. We can not exclude for sure, that the patient in his eighties was a case of merely asymptomatic colonization with a strain acquired in the hospital. There is no consensus definition for severe CDAD, nor is there agreement as to the most important clinical indicators that should be used to differentiate severity (11,12). Clinicians in the setting of the Quebec outbreak identified a white blood cell count >20,000 cells/microL and an elevated serum creatinine as potential indicators of complicated disease (10). A group in the United States devised a scoring system to identify patients with severe infection by giving one point each for age >60 years, temperature >38.3ºC, serum albumin <2.5 mg/dL (25 g/L), or peripheral white blood cell count >15,000 cells/microL within 48 hours of enrollment; two points were given for endoscopic evidence of pseudomembranous colitis or treatment in the intensive care unit, and patients with two or more points were considered to have severe disease [12].

The number of cases of enterocolitis due to C. difficile (ICD10: A04.7) reported by Austrian hospitals has drastically increased during the last few years: from 813 in 2002 (including 55 lethal cases) to 2,192 in 2006 (including 150 lethal cases). This constitutes a 3.7-fold increase of the number of reported cases with CDAD between 2002 and 2006. The potential problem of reporting bias for gastroenteric diseases has been addressed recently [13]. However, Burckhardt el al. even reported a six-fold increase of the yearly average of C. difficile incidence rates for a province in neighboring Germany for the same period of time [14].

The occurrence of autochthonous cases of C. difficile PCR ribotype 027 is just another argument underlining the urgent need for the implementation of a C. difficile surveillance system throughout Austria. Given the epidemic potential and the severity of the disease, especially among the elderly, surveillance of C. difficile must be introduced along with enhanced prevention and treatment strategies [15]. We strongly advise microbiological laboratories to perform microbiological cultures on toxin-positive stool samples and to apply typing methods on all isolates of severe clinical cases of C. difficile associated disease. For laboratories using capillary-sequerencer-based PCR ribotyping, the web based WEBRIBO®-system (http://webribo.ages.at) allows fast and reliable identification of PCR-ribotype patterns.

Acknowledgments

We are grateful to Jon Brazier from the University Hospital of Wales (Anaerobe Reference Laboratory, NHLS Microbiology Cardiff) for confirming the microbiological results.

References